# Binx Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/binx-health

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, US
- Website: https://mybinxhealth.com/
- Total disclosed funding: $188M
- Latest round: Series F (Apr 3, 2024)
- Investors on record: 17

## About

Founded in 2005 and based in Massachusetts, US, Binx Health Inc., formerly Atlas Genetics, operates as a diagnostics company developing ultra-rapid point-of-care tests for infectious diseases. John Clarkson and Pavel Rodyukov are the co-founders of the company. The firm has grown through various fundraising starting with an unspecified round (2006), Series A (2008), grant (2009) Series B (2014), Series C (2015), Series D (2017), and another unspecified round in 2020. In May 2021, the firm raised USD 104 million in Series E funding led by OrbiMed Advisors including Alta Life Sciences, ArrowMark Partners, Hildred Capital Partners, and Parian Global Management. Further in December 2023, Binx Health Inc. was acquired by Imaware, Inc., from Alta Life Sciences, ArrowMark Partners, EQT Life Sciences, Hildred Capital Partners, etc.

The Company’s binx io is a first-of-its-kind FDA-cleared, CLIA-waived, highly sensitive and specific, point-of-care (POC) diagnostic testing platform and is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)–the two most notifiable STI conditions. Binx Health's solutions are designed to break down screening barriers through discreet patient-tailored digital approaches that complement traditional brick-and-mortar care. In addition to binx io, the organization offers a comprehensive digital program that includes access to evidence-based testing, counseling, treatment, and follow-up aimed at increasing testing and reducing infection spread.

## Funding rounds

- Series F, Apr 3, 2024 — EQT Life Sciences, Hildred
- Series E, May 27, 2021, $104M — OrbiMed Advisors, EQT Life Sciences, Johnson & Johnson Innovation, ArrowMark Partners, Hildred, Parian Global Management, Alta Life Sciences
- Series D, Jan 23, 2017, $35M — Novartis Venture Fund, EQT Life Sciences, Johnson & Johnson Innovation, BB Biotech, Technology Venture Partners, Consort Medical PLC, RMI Partners, Guangzhou Wondfo Biotech Co Ltd
- Series C, Jan 29, 2015, $20M — Novartis Venture Fund, Technology Venture Partners, EQT Life Sciences, Johnson & Johnson Innovation, BB Biotech, Consort Medical PLC, RMI Partners
- Series B, Apr 29, 2014 — Novartis Venture Fund, EQT Life Sciences, Johnson & Johnson Innovation, BB Biotech, Consort Medical PLC, YFM Venture Finance Limited
- Series B, Jun 1, 2010, $24M — Novartis Venture Fund, EQT Life Sciences, Johnson & Johnson Innovation, BB Biotech, Consort Medical PLC
- Series A, Feb 13, 2008, $4.2M — Technology Venture Partners, Finance South West, IQ Capital, South West Angel and Investor Network

## Investors

- Technology Venture Partners — Series A, Series C, Series D
- Finance South West — Series A
- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Series A
- South West Angel and Investor Network — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C, Series D, Series E, Series F
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C, Series D, Series E
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series B, Series C, Series D
- Consort Medical PLC — Series B, Series C, Series D
- YFM Venture Finance Limited (https://capitalatlas.ai/funds/yfm-venture-finance-limited) — Series B
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series C, Series D
- Guangzhou Wondfo Biotech Co Ltd — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E
- ArrowMark Partners — Series E
- Hildred (https://capitalatlas.ai/funds/hildred) — Series E, Series F
- Parian Global Management (https://capitalatlas.ai/funds/parian-global-management) — Series E
- Alta Life Sciences — Series E